NCT06055881

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease

Conditions

• Breast Carcinoma
• Anatomic Stage IV Breast Cancer AJCC v8
• Metastatic Breast Cancer

Interventions

Type	Name	Description
PROCEDURE	Biospecimen Collection	Undergo blood sample collection
OTHER	Surveys	Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and "Was it Worth It" questionnaire.
RADIATION	Stereotactic Body Radiation Therapy (SBRT)	Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .
PROCEDURE	Computed Tomography	Undergo CT, MRI and/or PET/CT
PROCEDURE	Magnetic Resonance Imaging	Undergo CT, MRI and/or PET/CT
PROCEDURE	Positron Emission Tomography	Undergo CT, MRI and/or PET/CT

Timeline

• Start date: 2023-10-23
• Primary completion: 2027-05-01
• Completion: 2032-05-01
• First posted: 2023-09-28
• Last updated: 2026-02-06

Locations

2 sites across 1 country: United States